KERI LAZURE: Open Payments
NPI 1902864622 · BELLEVUE, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,026 in 54 payments from 17 companies in 2025. Trend: 2023 $989 · 2024 $1,412 · 2025 $1,026
Food & beverage: $1,026
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 15 | $187 |
| AstraZeneca Pharmaceuticals LP | 7 | $176 |
| Novo Nordisk Inc | 8 | $146 |
| Astellas Pharma US Inc | 3 | $91 |
| PFIZER INC. | 3 | $70 |
| ABBVIE INC. | 3 | $70 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Exact Sciences Corporation | 2 | $30 |
| Edwards Lifesciences Corporation | 1 | $24 |
Products named: MOUNJARO, Wegovy, Veozah, PAXLOVID, Kerendia, REXULTI, QULIPTA, UBRELVY.
Industry payments across NE — which companies pay providers there.
